395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

K.H Jung,S.J Luen,M Oliveira,J Sohn,S-A Im,S Wander,S.A Hurvitz,A Sonnenblick,V Breton,A Collier,S Deb,H Ngo,R Schwab,C Shemesh,J Zhu,C Hernando Melia

doi:10.1016/j.annonc.2023.09.572

395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

K.H Jung, S.J Luen + Show 14 more

https://doi.org/10.1016/j.annonc.2023.09.572

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Oct 1, 2023

Affiliation: University of Ulsan, Peter MacCallum Cancer Centre, Yonsei University, Seoul National University, Tel Aviv Sourasky Medical Center, Genentech

#Ipatasertib #Breast Cancer + Show 2 more

Abstract
Full-Text PDF
Similar Papers

Abstract

395P Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Full Text